Obese
Conditions
Brief summary
This study is being done to understand how chronic inflammation affects muscle function and responses to exercise.
Interventions
DIAGNOSTIC_TESTTreadmill Test
Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).
DIAGNOSTIC_TESTStrength Test
Measure the strength of leg muscles by kicking against a machine with resistance.
DIAGNOSTIC_TESTDual-Energy X-Ray Absorptiometry
Body composition measurement.
PROCEDUREMuscle Biopsy
Obtain a small piece of muscles from the upper part of the legs
PROCEDUREFat Biopsy
Fat sample taken from abdomen
DIAGNOSTIC_TESTResting Energy Expenditure
Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.
DIAGNOSTIC_TESTMagnetic resonance imaging
MRI on upper leg to look at fat and muscle
Sponsors
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Obese men and women ≥ 20 and ≤ 45 years of age.
Exclusion criteria
* Diabetes or fasting plasma glucose \>126 mg/dL * Anemia (female subjects hemoglobin of \<11 g/dl and male subjects hemoglobin \<12 g/dl) * Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment) * Renal failure (serum creatinine \> 1.5mg/dl) * Chronic active liver disease defined as aspartate aminotransferase (AST)\>144 IU/L or alanine transaminase (ALT) \>165 IU/L) * Oral warfarin group medications or history of blood clotting disorders. * Smoking * Pregnancy or breastfeeding * Alcohol consumption greater than 2 glasses/day or other substance abuse * Untreated or uncontrolled hypothyroidism * Debilitating chronic disease (at the discretion of the investigators)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in muscle protein synthesis | Baseline, post-exercise approximately 8 hours | Skeletal muscle protein synthesis will be measured from the rate of incorporation of infused amino acids measured by mass spectrometry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in mRNA expression of exercise responsive genes | Baseline, post-exercise approximately 8 hours | Measure messenger ribonucleic acids (mRNAs) expression on exercise responsive genes |
| Change in expression and activation (phosphorylation) of signaling proteins | Baseline, post-exercise approximately 8 hours | Phosphorylation is a common mechanism for the regulation of receptor function |
Countries
United States
Contacts
Primary ContactRachel Passehl
Outcome results
None listed